This is depressing. Mimetogen gets a dry eye deal with BAusch and Lomb. Mimetogen weaves their trial as a winner. But read what mimetogen themselves stated:
"Results: The prespecified primary endpoints were not met."
They had the oveall cornea. They flopped. But next Mimetogen says:
"In a subgroup defined by higher symptom scores during the run-in period, significant treatment effects (P , 0.05) were observed for diary symptoms for both MIM-D3 doses. Ocular adverse events were mild and not considered to be treatment-related."
RGRX and TB 4 is a mirror imahgge of this trial. RGRX flopped in a "pre specified" zone...as did Mimetogen....but both Mimetogen and RGRX scored nicely in cornea subsections. However, Mimetogen only in ONE subsection, RGRX got huge statistical win in TWO corneal subsections. But Mimetogen gets the money deal, and RGRX is ugly duckling. Way to go Finkelstein.